Coronavirus company news summary – Biocogniv and Research Partners study an AI tool to assist clinical labs in Covid-19 testing – CSIR-CCMB and Apollo hospitals collaborate on rapid and safe Covid-19 testing kits

11 December 2020 (Last Updated December 11th, 2020 09:47)

Applied BioCode has received Emergency Use Authorisation (EUA) from the US Food and Drug Administration (FDA) for the use of its BioCode® SARS CoV-2 molecular diagnostic assay along with pooled patient samples. The EUA permits BioCode to carry out pooled testing of up to five individual patient samples suspected to be infected with the SARS-CoV-2 virus.

Advanced MedTech Holdings (AMTH), a Singapore-based medical technology firm, announced that the RESOLUTE 2.0 test kit it co-developed with A*STAR and DSO National Laboratories has been authorised by the Health Sciences Authority (HSA) for deep-throat saliva (DTS) SARS-CoV-2 testing. AMTH holds the manufacturing and distribution rights for the test kits, which is easy-to-use and reduces the risk of virus spread.

Researchers from the University of Vermont and Cedars-Sinai have collaborated to study the performance of a Biocogniv’s COVID™ software. The team found that the artificial intelligence (AI) tool had high accuracy in predicting the probability of Covid-19 infection using routine blood tests, which can help hospitals reduce the number of patients referred for scarce PCR testing.

The Indian Council for Scientific and Industrial Research-Centre for Cellular and Molecular Biology (CSIR-CSMB) and Apollo Hospitals have collaborated to jointly manufacture and commercialise a dry swab test, Direct Amplification rapid RT-PCR (DArRT-PCR) for Covid-19 detection. The DARrT-PCR is cost effective and will be made available across India through the Apollo Hospitals network.